New startup ideas · Health and bio · Healthcare and bio

startup idea

Benchline

A regulated marketplace that puts any lab test on any clinic's benchtop.

Benchline builds one cleared benchtop analyzer and runs the two-sided marketplace on top of it: assay developers publish cartridge tests through Benchline's shared regulatory rails, and independent clinics, pharmacies and veterinary practices buy tests per run.

Marketplace
Small business
$10-100B market
Collapses a cost 10x
Global from day one

3/5

venture judge

similar startups, last 2 years (78 all-time)

79%

of 3 nearest real companies still alive

yes

8 matching federal grants and programs

Direction supported by government programs and grants

Test it before you build it

$1,400 · 4 weeks · 30 prospects

For $1,400 and 4 weeks, prove independent veterinary and primary care practices will commit money and volume to a benchtop analyzer that turns a $100 two-day send-out into a $12 run in minutes.

Riskiest assumption · Owners of independent veterinary and primary care practices will commit money and stated volume now to move their highest-volume panels onto an open-cartridge benchtop at a tenth the per-run price, despite standing IDEXX, Labcorp, Quest and distributor relationships.

1Focus group: who and where

The owner-operator of an independent 1-3 doctor practice: a veterinarian paying $30-45 per run on in-house IDEXX or Abaxis cartridges or sending panels out, or a primary care physician-owner sending chemistry and thyroid panels to Labcorp or Quest and waiting two days for results.

where to find 30 · State veterinary medical association member directories (Texas VMA and Florida VMA publish searchable practice lists); the Veterinary Information Network community where practice owners compare lab costs; the Fetch dvm360 conference exhibit floor for face-to-face pitches; Henry Schein and Patterson Veterinary distributor reps as a channel source; state medical board license rolls filtered to solo family medicine for the physician side.

2Sell first, build later

A first-wave placement: the analyzer installed free in the practice, the two highest-volume panels on the menu at launch, cartridges shipped monthly, go-live inside a promised quarter; vet practices first, human clinics queued behind clearance.

the ask · $12 per cartridge run, price locked for year one; $500 refundable reservation per veterinary practice; $0 down but a volume-stating LOI for human clinics.

a real yes · A real yes is a paid $500 vet reservation or a signed clinic LOI with a stated monthly volume and go-live window; 'we'd try it', unsigned interest and distributor compliments do not count.

3Small experiments

The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.

1. Vet placement reservation pitch
$300 · 10 days
Call 15 veterinary practice owners pulled from the Texas and Florida VMA directories. Walk each through a one-page spec and price sheet, CBC and chemistry panels at $12 a run against their last invoice, analyzer placed free, and ask for a $500 refundable reservation for one of 25 first-wave placements. Collect a copy of a recent reference-lab or cartridge invoice on every call to audit the 10x claim.
keep going if · 5 of 15 owners say yes on the call and 4 pay the $500 reservation within a week; audited invoices show a real cost of $60-plus per panel
2. Human clinic LOI test
$200 · 12 days
Call 10 independent primary care owners from state license rolls. Money cannot move on an uncleared human diagnostic, so ask instead for a signed non-binding LOI stating projected monthly run volume at $12 a run and a named go-live window contingent on clearance and CLIA waiver.
keep going if · 4 of 10 sign LOIs committing 100 or more runs per month
3. Distributor channel check
$900 · 10 days
Take a one-day exhibit pass to Fetch dvm360 and book 5 conversations with Henry Schein, Patterson Veterinary and McKesson Medical-Surgical diagnostics reps. Test whether they would carry an open-cartridge analyzer, at what margin, and which accounts they would demo it to.
keep going if · 2 of 5 reps confirm in writing they would carry it at a 20-30 percent margin and name 10 accounts for a demo

4Collect a deposit up front

Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.

$500

per prospect, refundable

how · A refundable placement reservation invoiced to the veterinary practice with a one-page reservation agreement signed by the owner; veterinary diagnostics need no FDA clearance, so a vet practice can legally pay today, which is exactly why the wedge starts there. Human clinics sign a dated LOI instead, because taking money for an uncleared human diagnostic is neither legal nor credible. set up: Stripe Invoicing ↗

what it reserves · One of 25 first-wave placements, free device installation, and the $12 per cartridge price locked for year one.

refund · Refunded in full on request any time before the analyzer ships, and automatically if the promised placement quarter is missed.

target · 8 paid vet reservations plus 4 clinic LOIs from 30 conversations within 30 days

before taking money · Human in-vitro diagnostics require FDA clearance or waiver and CLIA compliance, so take no money and run no patient sample on the human side before clearance; keep every paid commitment in the veterinary channel.

Go: build it if

8 or more paid vet reservations ($4,000 held), 4 or more clinic LOIs totaling 400-plus monthly runs, and at least 2 distributor reps willing to carry it: commit to the analyzer build and the first assay filings.

Kill: stop if

Fewer than 4 reservations after 25 vet pitches, or audited invoices show real per-panel cost under $40, which erases the 10x price collapse the whole card rests on: stop.

5 Scripts to run itoutreach message, landing copy, deposit terms · click to open

outreach message

You're paying $30-45 a run on in-house cartridges or sending panels to a reference lab and waiting two days while the client waits on hold. I'm building a benchtop analyzer with open cartridges: the same CBC and chemistry panels at $12 a run, device placed free, results in minutes. We're reserving 25 first-wave placements for independent practices. Do you have 20 minutes this week to put the per-run math against your last lab invoice?

landing page

Your highest-volume panels on your bench: $12 a run, in minutes. $500 refundable reservation places the analyzer free and locks $12 per cartridge for year one. Reserve one of 25 first-wave placements.

deposit terms

Your $500 reserves one of 25 first-wave analyzer placements: free installation and a $12 per cartridge price locked for your first year. It is fully refundable on request any time before your analyzer ships, and refunded automatically if we miss the promised placement quarter. Cartridge billing starts only after your first live run.

Would you run this test?

One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.

Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.

Scorecard

One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.

Idea Score, 0-100 · raw 38.1 x 1.61

Crowded

competition: more crowded than 88% of ideas · headwind x0.56

+4.6

government priorities, secondary (118 matching grants)

Trend

Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.

Entrants 2025-26 vs 2023-24 (similar companies)23
Rounds announced 2025+ in the sector69
Sector direction (live batch)100
2026 trend analyst0

Demand

Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.

YC asks for it (current RFS: idea / sector)30
Someone already pays (similar companies, recent / all-time)100
Operator judge: real pain50

100x potential

Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.

Venture judge50
Market size axis67
Moat axis100
Neighbours still alive76
Technologist judge100

Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were regulated, marketplace, puts, lab, test, clinic, benchtop, builds.

The idea in full

What: Benchline builds one cleared benchtop analyzer and runs the two-sided marketplace on top of it: assay developers publish cartridge tests through Benchline's shared regulatory rails, and independent clinics, pharmacies and veterinary practices buy tests per run. A panel that costs a small practice 100-plus dollars and two days as a send-out to a central lab runs on the bench in minutes at roughly a tenth of the price, with Benchline taking a cut of every cartridge.
Why now: Point-of-care hardware is getting funded again in a cluster that added 199 new companies in 2024 alone - YC X26's Lumius is building 3D ultrasound anyone can use and 500 Global's Carevision pitches 60-second cardiometabolic screening - but each of these devices ships as a closed, single-vendor system with one test menu.
Wedge: first customer and entry point: Start with two or three high-volume CLIA-waived-class assays for independent primary care and veterinary clinics, sold through existing diagnostics distributors who already own those relationships, before opening the developer side of the marketplace.
Path to 100x: In-vitro diagnostics is a market in the tens of billions, held today by central labs whose send-out pricing Benchline undercuts 10x. If the installed base reaches critical mass, every new assay developer must launch on Benchline to reach clinics and every new clinic buys the device to access the assay catalog - app-store take-rate economics with two-sided lock-in that makes decentralized testing winner-take-most.
Ceiling: Incumbent central labs cut send-out prices before the installed base reaches critical mass, freezing Benchline at a niche of remote and veterinary sites.
Closest real companies, as the generator saw them: Lumius and Carevision Inc. are single-device, single-menu point-of-care companies; Rebio Health builds one medical device for one indication. Benchline is the market between assay developers and clinics, not another closed instrument.
Main risk: The first assay clearances take so long and cost so much that the company burns out before the developer side of the marketplace exists.

Five judges

Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).

Venture investor
3/5
App-store economics on a cleared analyzer is a genuine power-law shape, but assay clearances gate the developer side for years.
Bootstrapper
1/5
Assay clearances plus a cleared benchtop analyzer are the exact hardware-and-regulatory prepay this lens refuses.
Operator
3/5
A 100-dollar two-day send-out collapsing to minutes at a tenth the price is money clinics already spend, but assay clearance delays the payoff for years.
Technologist
5/5
One cleared analyzer plus open cartridge rails for third-party assay developers is hardware, regulatory and platform work that compounds with every assay added.
Risk
2/5
Cleared analyzer plus per-assay clearances make regulatory timelines the single point of failure, with distributor relationships owning the clinic channel Benchline needs.
trends
1/5
Multi-year assay clearances mean any 2026 window closes before launch, and 'hardware getting funded again' was equally said in 2021.

Similar startups in the directory

Companies whose pitch matches most of the idea's terms (regulated, marketplace, puts, lab, test, clinic, benchtop, builds): 78 all-time, 22 from the last two years. Same matching as Idea Check.

Archangel Healthyc F26 · 2026 · AI infra and computealive
Infra to make AI safe enough to practice medicine
Standard Medicalyc S26 · 2026 · Healthcare and bioalive
A primary care clinic where AI earns clinical autonomy
Slideflow Labsalchemist Alchemist Class 41 · 2026 · Healthcare and biounchecked
Empowering next-gen precision oncology with scalable, in-house AI biomarkers from routine pathology slides.
Spotef EF London 2021 · 2021 · Healthcare and bioalive
API for at-home clinical sample collection.
LEAH Labsyc W19 · 2019 · Healthcare and bioalive
Living therapies for pets first, and their people next
iLabServiceyc S18 · 2018 · B2B SaaSalive
AIoT monitoring, workflow, and evidence systems for regulated labs.
Confident LIMSyc S15 · 2015 · B2B SaaSalive
Laboratory Information Management System (LIMS) serving…
Guardant Healthpear · Healthcare and biopublic
Precision oncology company focused on transforming patient care and conquering cancer with data
Acyclic Labsyc F26 · 2026 · Agent infrastructurealive
Agent swarms that make long-running tasks exponentially faster
Chorah Labsplugandplay PnP 2026 · 2026 · Vertical AI agentsalive
At Chorah Labs we are building ARI (Automated Regulatory Intelligence);an AI-native platform building compliance-by-design tools for biopharma and advanced therapy companies, automating regulatory, CMC, and manufacturing workflows across the IND-to-GMP lifecycle.
Levisonicsplugandplay PnP 2026 · 2026 · Healthcare and bioalive
Levisonics is developing a drop-of-blood, point-of-care coagulation analyzer that delivers in a single test the comprehensive clotting insights that today require multiple separate lab and point-of-care tests.
Rasynyc S26 · 2026 · Healthcare and bioalive
Making chemicals 100,000x faster

Run this as an Idea Check →

The generator's reference companies

Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.

Public money in this direction

US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.

grants and programs matching the idea

1595

startup-relevant grants in Healthcare and bio

$854M

awarded in the sector, tracked

118

opportunities open now in the sector

IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ringawardhigh relevance
NIH / NICHD · SBIR phase II · $1M · posted 2026-09-25
Low-cost technology for image-guided photodynamic treatment of oral lesions in resource-limited settingsawardhigh relevance
NIH / NCI · STTR phase I · $315K · posted 2026-09-18
High-throughput kinetic system for small-molecule drug discoveryawardhigh relevance
NIH / NCATS · SBIR phase II · $1M · posted 2026-09-15
Developing a DACH1 specific detection assay that predicts therapy response in advanced prostate cancer.awardhigh relevance
NIH / NCI · SBIR phase I · $399K · posted 2026-09-04
mHealth AI for Remote & Rural Chronic Disease Detection and Managementawardhigh relevance
NIH / NHLBI · SBIR phase I · $406K · posted 2026-09-01
The Rotational Femoral Nail: Late Stage Translation from Lab to Marketplaceawardhigh relevance
NIH / NIAMS · SBIR phase I · $300K · posted 2026-09-01
FlyBand-Peds: Evaluating Biomechanics of Integrated Exoskeleton Footwear for Pediatric Charcot-Marie-Tooth Diseaseawardhigh relevance
NIH / NICHD · SBIR phase I · $306K · posted 2026-08-01
I-Corps: Translation potential of a cell culture technology that synchronizes cellular circadian rhythms through precise temperature oscillationsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-07-24

All public money by sector →

Market signal

What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.

Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch

Healthcare and bio: companies, trend and grants →

Design attributes

The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.

Buyer: Small business
Business model: Marketplace
Path to 100x: Collapses a cost 10x
Market size: $10-100B market
Capital intensity: Capital-heavy (hardware, bio, infra)
Speed to revenue: R&D first, revenue after 3 years
Technical depth: Deep tech: ML, hardware, bio
Go-to-market: Partners and channels
Moat: Network effects
Geography: Global from day one
Regulation: Heavily regulated
Vibe: Boring business